Physician profile
Timothy J Craig
NPI 1609825306
$564,019.12
in general payments reported to CMS, 2019-2025
33 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $52K · 2021: $76K · 2022: $48K · 2023: $148K · 2024: $87K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Consulting Fee: $54K · Travel and Lodging: $43K · Food and Beverage: $8,376 · Honoraria: $6,600 · Education: $12.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $222,720.77 |
| Consulting Fee | $54,319.50 |
| Travel and Lodging | $42,974.90 |
| Food and Beverage | $8,376.29 |
| Honoraria | $6,600.00 |
| Education | $12.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $293,985.68 | 2019-2025 | Andembry, Berinert, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $101,992.29 | 2020-2025 | Glassia, Takhzyro |
| Grifols USA, LLC | $32,694.32 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Biocryst Pharmaceuticals, INC. | $26,758.11 | 2019-2025 | Orladeyo |
| Biocryst US Sales Co., LLC | $17,796.56 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $13,836.61 | 2019 | |
| Shire North American Group INC | $11,527.55 | 2019 | |
| Ionis Pharmaceuticals, INC. | $10,914.04 | 2025 | Dawnzera, Donidalorsen |
| Genzyme Corporation | $9,742.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,901.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $7,707.41 | 2019-2023 | Arexvy |
| Pharming Healthcare, INC. | $6,632.89 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $6,490.59 | 2021-2025 | |
| Insmed, INC. | $5,270.80 | 2019-2025 | Brinsupri, Arikayce |
| Spark Therapeutics, INC. | $3,763.75 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $1,767.50 | 2021-2022 | |
| Celgene Corporation | $1,120.00 | 2019 | |
| Hexal Ag | $1,012.50 | 2025 | |
| Grifols Shared Services North America, INC. | $903.79 | 2022-2023 | Prolastin-C Liquid |
| Biomarin Pharmaceutical INC. | $422.42 | 2021-2023 | |
| Vifor Pharma, INC. | $385.99 | 2024-2025 | Veltassa |
| Horizon Therapeutics Plc | $322.58 | 2022 | |
| Genentech USA, INC. | $262.79 | 2019-2024 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $199.03 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $172.40 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $160.52 | 2022-2023 | |
| Genentech, INC. | $157.90 | 2019-2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $48.62 | 2025 | Neffy |
| Amgen INC. | $35.90 | 2023-2024 | Tezspire, Actimmune |
| Dermavant Sciences, INC. | $32.91 | 2023 | Vtama |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.